Managing Attention Deficit Disorders | Skills Pool
Archivo del skill
Managing Attention Deficit Disorders
Structures ADHD evaluation in children with behavioral rating scales and medication trials. Use when evaluating pediatric ADHD, interpreting Vanderbilt/Conners scales, or managing stimulant therapy.
Structures the evaluation, diagnosis, and multimodal management of Attention-Deficit/Hyperactivity Disorder (ADHD) in children ages 4-18 using the AAP 2019 Clinical Practice Guideline, DSM-5 criteria, Vanderbilt Assessment Scales, evidence-based medication titration, and behavioral therapy coordination.
Why This Skill Exists
ADHD is the most commonly diagnosed neurobehavioral disorder of childhood, affecting approximately 9.4% of U.S. children ages 2-17. Despite high prevalence, it is both overdiagnosed (in populations with access) and underdiagnosed (in girls, minorities, and underserved communities). The AAP 2019 guideline mandates structured diagnostic criteria with multi-informant rating scales, age-stratified treatment recommendations, and systematic titration protocols. This skill enforces the guideline-based diagnostic pathway and treatment algorithm to prevent both missed diagnoses and inappropriate stimulant prescribing.
Checkpoint A — Intake Verification
Required Intake Questions
What is the child's age (4-18 for AAP guideline application)?
Skills relacionados
What are the primary concerns (inattention, hyperactivity, impulsivity, or combination)?
In which settings do symptoms occur (home, school, social, sports)?
When did symptoms first appear (must be present before age 12 per DSM-5)?
Are there academic problems (grades, IEP/504, retention)?
Is there a family history of ADHD, mood disorders, anxiety, or substance use?
Are there symptoms of comorbid conditions (anxiety, depression, ODD, learning disability, tic disorder, ASD)?
What is the child's sleep pattern (sleep deprivation mimics ADHD)?
Has the child had vision and hearing screening?
Has the child been previously treated with medication for ADHD? What was the response?
Required Documents
Completed Vanderbilt Assessment Scales — Parent form AND Teacher form (or Conners-3, SNAP-IV)
Academic records (report cards, standardized test scores, teacher comments)
IEP/504 plan if applicable
Developmental history
Prior psychoeducational or neuropsychological testing (if done)
Vision and hearing screening results
DSM-5 requires symptoms in ≥ 2 settings. Teacher input is essential — do not diagnose ADHD without information from the school setting.
Step 1 — DSM-5 Diagnostic Criteria
Diagnostic Requirements
To diagnose ADHD, ALL of the following must be present:
Symptom threshold: ≥ 6 of 9 inattention symptoms AND/OR ≥ 6 of 9 hyperactivity-impulsivity symptoms (for age ≥ 17: ≥ 5 in either domain)
Duration: symptoms present for ≥ 6 months
Age of onset: several symptoms present before age 12
Pervasiveness: symptoms present in ≥ 2 settings (home + school)
Impairment: clear evidence that symptoms interfere with functioning
Exclusion: not better explained by another mental disorder
ADHD Presentation Types
Presentation
Criteria
Predominantly inattentive
≥ 6/9 inattention; < 6/9 H-I
Predominantly hyperactive-impulsive
< 6/9 inattention; ≥ 6/9 H-I
Combined
≥ 6/9 in both domains
Inattention Symptoms (9)
Fails to give close attention to details / careless mistakes
Difficulty sustaining attention in tasks or play
Does not seem to listen when spoken to directly
Does not follow through on instructions / fails to finish tasks
Difficulty organizing tasks and activities
Avoids or is reluctant to engage in tasks requiring sustained mental effort
Loses things necessary for tasks
Easily distracted by extraneous stimuli
Forgetful in daily activities
Hyperactivity-Impulsivity Symptoms (9)
Fidgets with hands/feet or squirms in seat
Leaves seat when remaining seated is expected
Runs about or climbs in inappropriate situations
Unable to play or engage in leisure activities quietly
First-line: FDA-approved medication with assent from the adolescent
Behavioral therapy should be offered, but medication is the primary treatment
Address driving safety, substance use risk, and organizational skills
Discuss medication continuity through transitions (college, employment)
Step 4 — Medication Management
Stimulant Medications (First-Line)
Methylphenidate Formulations
Formulation
Brand Examples
Duration
Starting Dose
Immediate-release
Ritalin
3-4 hours
5 mg BID-TID
Extended-release (OROS)
Concerta
10-12 hours
18 mg QAM
Extended-release (beaded)
Ritalin LA, Aptensio XR
8-10 hours
10-20 mg QAM
Transdermal patch
Daytrana
10-12 hours
10 mg/9 hr patch
Liquid
Quillivant XR
10-12 hours
20 mg QAM
Amphetamine Formulations
Formulation
Brand Examples
Duration
Starting Dose
Mixed amphetamine salts IR
Adderall
4-6 hours
5 mg QD-BID
Mixed amphetamine salts XR
Adderall XR
10-12 hours
5-10 mg QAM
Lisdexamfetamine
Vyvanse
12-14 hours
20-30 mg QAM
Dextroamphetamine
Dexedrine
4-6 hours
2.5-5 mg BID
Titration Protocol
Start at the lowest recommended dose
Titrate every 1-2 weeks based on response and side effects
Use Vanderbilt Follow-Up scales (parent + teacher) to assess response
Target: symptom reduction to < 6 positive items in affected domains + improved performance
If one stimulant class fails (methylphenidate): switch to amphetamine class (and vice versa) before moving to non-stimulant
Non-Stimulant Medications (Second-Line)
Medication
Class
Starting Dose
Notes
Atomoxetine
NRI
0.5 mg/kg/day × 3 days → 1.2 mg/kg/day
Onset 4-6 weeks; FDA black box: suicidal ideation monitoring
Guanfacine XR
Alpha-2 agonist
1 mg QHS
Sedation, hypotension; do not abruptly discontinue
Clonidine XR
Alpha-2 agonist
0.1 mg QHS
Similar to guanfacine; also treats tics
Viloxazine XR
NRI
100 mg QAM (6-11y); 200 mg QAM (12+)
Newer; less data on long-term outcomes
Side Effect Monitoring
Every visit: weight, height, heart rate, blood pressure
Appetite suppression: most common side effect; counsel on high-calorie breakfast, after-medication meals, bedtime snacks
Growth: plot height and weight on growth chart at every visit; calculate height velocity annually; temporary growth deceleration is common
Sleep: stimulants may cause insomnia; consider earlier dosing, shorter-acting formulation, or melatonin adjunct
Cardiovascular: routine ECG NOT recommended for healthy children; obtain ECG only if cardiac history, family history of sudden death, or abnormal cardiac exam
Tics: stimulants may unmask but generally do not cause tics; tics are not an absolute contraindication
Mood/behavior: monitor for rebound irritability, emotional lability, new anxiety
Step 5 — Behavioral and Academic Interventions
Evidence-Based Behavioral Therapy
Parent training programs: Triple P, Incredible Years, Parent-Child Interaction Therapy (PCIT)